Clinical Trial

Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

Study acronym: Re-HU-TREAT
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001/jamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-14.
Status change: Active, Not Recruiting → Recruiting 2025-08-20
Trial Details
NCT Number NCT06937788
Lead Sponsor Technische Universität Dresden
Conditions Atopic Dermatitis
Enrollment 240 participants
Start Date 2021-08-02
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-21